Supporting better health, one cell at a time
Mekonos is building the future of cell engineering with its system-on-a-chip, next-generation ex vivo delivery platform. The Mekonos platform utilizes semiconductor technology, microfluidics, and chemistry to unlock precision, scale and yield.
Unprecedented precision as cells are turned into therapeutic agents
Mekonos’ silicon nanoneedle-based delivery platform enables unique capabilities for high efficiency, high viability cell engineering. The ability to precisely control delivery of multiplexed cargo, including nuclear delivery, will open the doors to a new world of possibilities, including personalized medicine in a point-of-care setting.
How do we do this?
Semiconductor Chip Technology
We apply advanced semiconductor processes to develop unique chips with silicon nanoneedles for enhanced delivery of molecular cargo into cells. MEMS technology controls individual nanoneedles for precise single-cell delivery at scale.
Microfluidic Cell Trapping
We use microfluidics to flow cells on and off our platform, as well as to capture individual cells in specific sites. Each cell-trapping site is aligned with a single needle – “one needle, one cell” – for carefully controlled, consistent delivery across the entire chip.
Surface Chemistry
We use proprietary surface chemistry to load cargo (DNA, RNA or proteins) onto our solid silicon nanoneedles. By manipulating the kinetics of our surface chemistry, we can control the release of payloads into target cells, enabling a new level of dose control in cell engineering.
Blowing past traditional cell and gene therapy barriers
Our scalable platform offers the delivery of any molecular cargo to any cell, supporting cell and gene therapy programs from the R&D stage through the manufacturing process. Learn more about the unique capabilities unlocked by our nanoneedle-based delivery platform.
Partner with Mekonos
Let’s kickstart a new era of cell therapy together.